Progress and prospects: Hurdles to cardiovascular gene therapy clinical trials

Gene Therapy

Volumn 18, Issue 8, 2011, Pages 743-749

  Hedman, M ^a   Hartikainen, J ^a,b   Yla Herttuala S ^a,b,c  

^a Heart Center   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

angiogenesis; cancer; cardiovascular diseases; clinical trial; safety; vectors

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; PLACEBO; PLASMID DNA; RECOMBINANT FIBROBLAST GROWTH 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN C;

ADENOVIRUS 5; AMPUTATION; ANGINA PECTORIS; ANGIOGENESIS; ARTERY DISEASE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR SYSTEM; CELL MEMBRANE; CELL THERAPY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; EXERCISE TOLERANCE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; INFLAMMATION; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PERICARDIUM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; REVASCULARIZATION; REVIEW; RNA ANALYSIS; SKELETAL MUSCLE; THORACOTOMY; THORAX PAIN; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH; ULCER; VASOSPASM; WALKING;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; PATIENT SELECTION; PLACEBO EFFECT;

EID: 80051801809     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.43     Document Type: Review

References (51)

1. Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026. (Pubitemid 46349500)
2. Rissanen TT, Ylä-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007; 15: 1233-1247. (Pubitemid 46965318)
3. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053-2058. (Pubitemid 34680967)
4. Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133. (Pubitemid 36124280)
5. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16: 972-978. (Pubitemid 351587109)
6. Rajagopalan S, Mohler ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938. (Pubitemid 37296537)
7. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-1365. (Pubitemid 36350732)
8. Reilly JP, Grise MA, Fortuin FD, Vale PR, Schaer GL, Lopez J et al. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol 2005; 18: 27-31. (Pubitemid 40468771)
9. Laitinen M, Hartikainen J, Hiltunen MO, Eränen J, Kiviniemi M, Närvänen O et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270. (Pubitemid 30080384)
10. Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio angiogenesis trial (KAT). Circulation 2003; 107: 2677-2683. (Pubitemid 36667240)
11. Hedman M, Muona K, Hedman A, Kivelä A, Syvänne M, Eränen J et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Therapy 2009; 16: 629-634.
12. Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007; 50: 1038-1046 (Pubitemid 47354223)
13. Cardium therapeutics. Summary of generx clinical development. Cardium therapeutics, 2011 (in press), http://www.cardiumthx.com.
14. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W et al. Euroinject one group. direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject one trial. J Am Coll Cardiol 2005; 45: 982-988. (Pubitemid 40432426)
15. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006; 13: 1503-1511. (Pubitemid 44574158)
16. Corautus Genetics. Corautus announces termination of patient enrollment in GENASIS severe angina clinical trial. Corautus Genetics, 2008.
17. Stewart DJ, Kutryk MJB, Fitchett D, Freeman M, Camack N, Su Y et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009; 17: 1109-1115
18. ClinicalTrials.gov. A study to treat patients whose chronic angina symptoms are not relieved by medication and have an area of the heart that cannot be treated by standard therapies. ClinicalTrials.gov, 2011 (in press), http://www.clinicaltrials.gov.
19. ClinicalTrials.gov. Angiogenesis in women with angina pectoris who are not candidates for revascularization (AWARE). ClinicalTrials.gov 2011 (in press) http://www.clinicaltrials.gov.
20. ClinicalTrials.gov. Induced angiogenesis by genic therapy in advanced ischemic cardio-myopathy (THEANGIOGEN). ClinicalTrials.gov 2011 (in press) http://www.clinicaltrials.gov.
21. ClinicalTrials.gov. Safety study of gene transfer agent MYDICARs (AAV1/SERCA2a) to treat heart failure. ClinicalTrials.gov, 2011 (in press), http://www.clinicaltrials.gov.
22. ClinicalTrials.gov. Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions (TAMARIS). ClinicalTrials.gov 2011 (in press) http://www.clinicaltrials.gov.
23. Maier LS, Baumhäkel M, Böhm M. Hotline sessions presented at the American college of cardiology congress 2009. Clin Res Cardiol 2009; 98: 345-352.
24. Powell RJ, Dormandy J, Simons M, Morishita R, Annex BH. Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogen-esis clinical trial. Vasc Med 2004; 9: 193-198. (Pubitemid 40124084)
25. Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138-2143. (Pubitemid 32458322)
26. Wirth T, Hedman M, Mäkinen K, Manninen H, Immonen A, Vapalahti M et al. Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr Drug Safety 2006; 1: 253-257.
27. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997; 8: 1645-1650. (Pubitemid 28031582)
28. Su H, Huang Y, Takagawa J, Barcena A, Arakawa-Hoyt J, Ye J et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Therapy 2006; 13: 1495-1502. (Pubitemid 44567147)
29. van Kempen LC, Leenders WP. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. Eur J Cell Biol 2006; 85: 61-68. (Pubitemid 43137111)
30. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009; 335: 261-269.
31. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003; 92: 1098-1106. (Pubitemid 36665855)
32. Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Ordén MR, Kholová I et al. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 2005; 112: 3937-3946. (Pubitemid 43739492)
33. Korpisalo P, Rissanen TT, Bengtsson T, Liimatainen T, Laidinen S, Karvinen H et al. Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs. Cardiovasc Res 2008; 80: 263-270.
34. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132: 880-884. (Pubitemid 30346850)
35. Saaristo A, Tammela T, Timonen J, Ylä-Herttuala S, Tukiainen E, Asko-Seljavaara S. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J 2004; 18: 1707-1709. (Pubitemid 39561658)
36. Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M et al. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 2008; 115: 1916-1922.
37. Yamasaki M, Noma H, Funatsu H, Minamoto A, Mimura T, Shimada K et al. Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor. Int Ophthalmol 2009; 29: 161-167.
38. Lantry LE. Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications. Curr Opin Mol Ther 2007; 9: 592-602. (Pubitemid 350179099)
39. Kusumanto YH, Weel VV, Mulder NH, Smit AJ, Dungen JJ, Hooymans JM et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17: 683-691. (Pubitemid 43970708)
40. Lähteenvuo JE, Lähteenvuo MT, Kivelä A, Rosenlew C, Falkevall A, Klar J et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogen-esis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 2009; 119: 845-856.
41. Hao X, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, Brodin LA et al. Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc Res 2007; 73: 481-487. (Pubitemid 46084927)
42. Yamashita Y, Shimada M, Tachibana K, Harimoto N, Tsujita E, Shirabe K et al. In vivo gene transfer into muscle via electro-sonoporation. Hum Gene Ther 2002; 13: 2079-2084. (Pubitemid 35417352)
43. Fichou Y, Ferec C. The potential of oligonucleotides for therapeutic applications. Trends Biotechnol 2006; 24: 563-570. (Pubitemid 44751217)
44. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004; 110: 1484-1491. (Pubitemid 39238028)
45. Matthews QL. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 2011; 1: 3-11.
46. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 2002; 4: 371-380. (Pubitemid 40277174)
47. Nicklin SA, White SJ, Nicol CG, Von Seggern DJ, Baker AH. In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Med 2004; 6: 300-308. (Pubitemid 40228047)
48. Gruchala M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I et al. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 2004; 6: 545-554. (Pubitemid 40228070)
49. Baldazzi F, Jørgensen E, Ripa RS, Kastrup J. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. Eur Heart J 2008; 29: 1819-1826.
50. Fukushima S, Varela-Carver A, Coppen SR, Yamahara K, Felkin LE, Lee J et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 2007; 115: 2254-2261. (Pubitemid 46685893)
51. Hiltunen MO, Turunen MP, Turunen AM, Rissanen TT, Laitinen M, Kosma VM et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000; 14: 2230-2236.